Biomarkers For Psychosis
Researchers at UC San Diego have elucidated novel methods to diagnose psychosis and bipolar disorder by measuring the relative amount of key protein biomarkers in psychotic and non-psychotic individuals. This technology includes a method to diagnose psychotic and non-psychotic bipolar disorder by measuring the relative expression of growth-associated protein 43 (GAP-43) or its mRNA in blood.The inventors successfully demonstrated this technology in a study of 35 patients with schizophrenia, 35 with bipolar disorder, and 35 matched non-psychiatric controls (the Stanley Array Collection maintained by the Stanley Medical Research Foundation). They found that the pre-synaptic protein GAP-43 was increased by 22 percent in psychotic bipolar and 18 percent in non-psychotic bipolar subjects compared to controls (Tian SY et al. 2007).
Patent Number: US8470299B2
Application Number: US2009600119A
Inventor: Tsuang, Ming T. | Everall, Ian P.
Priority Date: 15 May 2007
Priority Number: US8470299B2
Application Date: 13 Aug 2010
Publication Date: 25 Jun 2013
IPC Current: C12Q000168 | G01N003350 | G01N003368
US Class: 4240091 | 4350061 | 43500795
Assignee Applicant: The Regents of the University of California
Title: Biomarkers for psychosis
Usefulness: Biomarkers for psychosis
Summary: The methods are useful for diagnosing psychosis or bipolar disorder, where the bipolar disorder is non-psychotic bipolar disorder or psychotic bipolar disorder (all claimed).
诊断/治疗
其他疾病
Intellectual Property Info Intellectual Property Information: This invention is available for licensing in the United States. US patent to issue imminently. Related Materials GLATT, SJ et al., Comparative Gene Expression Analysis of Blood and Brain Provides Concurrent Validation Of SELENBP1 Up-Regulation In Schizophrenia, Proceedings of the National Academy of Sciences of the United States of America, Vol. 102(3), (25 Oct. 2005), pp. 15533-15538. Tech ID/UC Case 23230/2007-235-0 Related Cases 2007-235-0
KANAZAWA, T et al., The Utility of SELENBP1 Gene Expression as a Biomarker for Major Psychotic Disorders: Replication in Schizophrenia and Extension to Bipolar Disorder with Psychosis, American Journal of Medical Genetics Part B (Neuropsychiatric Genetics, AJMB-07-0187.R1(30664), (2007), 4 pages.
TIAN, SY et al., Immunoreactivity of 43KDa Growth-Associated Protein is Decreased in Post Mortem Hippocampus of Bipolar Disorder and Schizophrenia, Neuroscience Letters, (10 Jan 2007), 123-127.
美国
